Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345070 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 327
- Enrollment target
NCT02345070: Completed Phase 2 study, sponsored by Sanofi.
NCT02345070 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 327 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (146% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02345070, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 327 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis (IPF). Secondary Objectives: To evaluate the efficacy of 2 dose levels/regimens of SAR156597 compared to placebo on IPF disease progression. To evaluate the safety of 2 dose levels/regimens of SAR156597 compared to placebo in participants with IPF.
Primary Outcome
FVC is a standard pulmonary function parameter measured by spirometry and used to quantify respiratory capacity (inspiration and expiration). It is a widely used objective measure of disease status in participants with Idiopathic Pulmonary Fibrosis (IPF). The primary variable was recorded as percent (%) of predicted value, which takes into account the height, gender, and age of the participant. The outcome measure measured the change in lung function from baseline at week 52.
Interventions
- DRUG placebo
- DRUG SAR156597
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2017-08-14 |
| Phase | Phase 2 |
What the finished NCT02345070 record still lists
NCT02345070 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (146% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02345070 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02345070 about?
NCT02345070 is a clinical study titled "Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis". Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis (IPF). Secondary Objectives: To evaluate the efficacy of 2 dose levels/re...
What is the current status of trial NCT02345070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 327 participants. The study started on 2015-05-01. Estimated completion is 2017-08-14.
What interventions are being tested in trial NCT02345070?
The interventions under investigation include: placebo (DRUG), SAR156597 (DRUG).
Who is sponsoring clinical trial NCT02345070?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02345070's enrollment target sits among peer trials
327 146th of 2000 higher than 1,854 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI